NVIDIA (NVDA) Jumps Onto New Street’s “2026 Best Ideas List” on Exceptional Order Momentum TipRanks

Inhibrx Biosciences press release ( INBX ): Q4 GAAP EPS of -$2.11 misses by $0.03 . As of December 31, 2025, Inhibrx had cash and cash equivalents of $124.2 million. On March 18, 2026, the company entered into the First Amendment to the Loan and Security Agreement with Oxford Finance, LLC and received gross proceeds of $75.0 million. More on Inhibrx Biosciences Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too Seeking Alpha’s Quant Rating on Inhibrx Biosciences Historical earnings data for Inhibrx Biosciences Financial information for Inhibrx Biosciences

随着全国多地明确春假时间，今年春季旅游市场提前进入预订高峰期，旅游出行平台显示，国内机票搜索和预订量都出现增长。数据显示，截至目前，4月1日至6日国内航线机票预订量超225万张，同比增长约25%，近一周相关机票搜索及预订量环比上涨2倍。(央视新闻) 免责声明： 风险提示：本文内容仅供参考，不代表同花顺观点。同花顺各类信息服务基于人工智能算法，如有出入请以证监会指定上市公司信息披露平台为准。如有投资者据此操作，风险自担，同花顺对此不承担任何责任。

NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. “We are excited to enter 2026 with significant momentum as we continue to advance the development of our ProTide pipeline with the aim to deliver significantly improved treatment outcomes for patients with cancer,” said Hugh S. Griffith, NuCana’s Chief Executive Officer. “In late 2025, we presented compelling data from our Phase 2 NuTide:701 study at the annual European Society for Medical Oncology Immuno-Oncology Congress, evaluating NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma. These data demonstrated a favorable safety profile and evidence of clinical activity, including two partial responses, one of which was confirmed, and multiple cases of stable disease, including one patient whose disease converted to a complete metabolic response with no detectable active disease.” Mr. Griffith continued, “We expect to complete enrollment in the Phase 2 NuTide:701 expansion study in the first half of 2026, with final data expected later this year. We also plan to obtain regulatory guidance from the U.S. Food and Drug Administration regarding a potential registrational pathway for NUC-7738 in melanoma. In parallel, we are evaluating additional indications and combination strategies to further explore the therapeutic potential of NUC-7738.” Mr. Griffith concluded, “Earlier this year we appointed Theresa Bruce as our Chief Operating Officer....

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile Completed an oversubscribed $160 million PIPE financing led by leading healthcare investors in March 2026, strengthens balance sheet to support NDV-01 Phase 3 development On track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 Cash balance of $93.0 million as of December 31, 2025, plus gross proceeds of $160 million from March 2026 PIPE expected to fund operations through 2029, including completion of the NDV-01 RESCUE program Management to host a conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported audited financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update highlighting significant progress across its pipeline. “This has truly been a transformational year for Relmada, marked by significant progress with our lead program NDV-01,” said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics. “Our recently reported 12-month data for NDV-01 demonstrated durable complete responses with a favorable safety profile, reinforcing the program’s potential to become a best-in-class therapy for patients with non-muscle invasive bladder cancer. With a successful $160 million PIPE financing and regulatory alignment with the FDA on two registrational pathways, we believe that we are well positioned to advance NDV-01 into the Phase 3 RESCUE program in mid-2026. Our team is now focused on executing this plan and initiating the RESCUE registrational program as we wo...

Leading artificial intelligence firms need to convince an increasingly skeptical public that AI can be a force for good. But first… Three things to know: • Musk’s xAI is hiring credit experts, bankers to teach Grok finance • OpenAI to acquire startup Astral , expanding push into coding • Fluidstack drops out of marquee €10 billion AI project in France Finding a new AI messenger Over the years, AI leaders have suggested that advances in artificial intelligence may eventually help students learn better, accelerate scientific progress and potentially cure cancer, among other feats. Increasingly, however, that messaging appears to be falling on deaf ears. “AI is not very popular in the US right now,” OpenAI Chief Executive Officer Sam Altman told a room full of politicians, executives and financiers at a recent conference in Washington DC. “Data centers are getting blamed for electricity price hikes . Almost every company that does layoffs is blaming AI, whether or not it really is about AI.” Though more people are using AI than ever, many are also expressing negative sentiment about it in surveys, particularly in the US. A recent NBC News poll found 57% of Americans believe the risks of AI outweigh its benefits. That’s in line with a Gallup poll from mid-2025 showing half of those in the US were more concerned than excited about AI, up from 31% in 2021. (In China, trust in AI appears to be significantly higher.) Silicon Valley has faced backlash before, including concerns about the mental health risks from overusing smartphones and social media. Yet, the deteriorating public opinion about AI has been particularly stark. There has been growing community pushback to large data centers that strain power grids and water supplies ; a litany of lawsuits alleging people experience chatbot-induced delusions and psychosis; and various viral dystopian blog posts and proclamations about mass white-collar layoffs fueled by AI. “The industry is having a really hard time seeing this...

The following companies are expected to report earnings prior to market open on 03/20/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Milestone Pharmaceuticals Inc. (MIST)is reporting for the quarter ending December 31, 2025. The biomedical (gene) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.18. This value represents a 5.26% increase compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for MIST is -2.39 vs. an industry ratio of -3.40, implying that they will have a higher earnings growth than their competitors in the same industry. BitFuFu Inc. (FUFU)is reporting for the quarter ending December 31, 2025. The financial services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.01. This value represents a 107.14% decrease compared to the same quarter last year. FUFU missed the consensus earnings per share in the 1st calendar quarter of 2025 by -350%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for FUFU is 77.00 vs. an industry ratio of 0.70, implying that they will have a higher earnings growth than their competitors in the same industry. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Parkev Tatevosian, CFA has positions in Nvidia and Uber Technologies. The Motley Fool has positions in and recommends Nvidia and Uber Technologies. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

道瓊斯工業平均指數收報46,021點，跌203點。 標準普爾五百指數收報6,606點，跌18點。

格隆汇3月20日｜美国投资公司协会（ICI）：截至3月18日的一周，货币市场基金资产增加了386.8亿美元，达到了7.86万亿美元。

Consumer stocks fell late Thursday afternoon with the State Street Consumer Staples Select Sector SP Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles.

PVA TePla AG press release ( TPLKF ): FY consolidated revenue of EUR 244.3 million and EBITDA of EUR 25.3 million. Guidance for fiscal year 2026: Revenue of EUR 255 to 275 million, EBITDA of EUR 26 to 31 million. More on PVA TePla AG PVA TePla AG (TPLKF) Q4 2025 Earnings Call Transcript PVA TePla AG 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for PVA TePla AG Financial information for PVA TePla AG

In trading on Thursday, shares of the SPDR S&P Health Care Services ETF (Symbol: XHS) crossed below their 200 day moving average of $102.08, changing hands as low as $101.48 per share. SPDR S&P Health Care Services shares are currently trading down about 1% on the day. The chart below shows the one year performance of XHS shares, versus its 200 day moving average: Looking at the chart above, XHS's low point in its 52 week range is $87.64 per share, with $112.085 as the 52 week high point — that compares with a last trade of $101.75. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Reynolds Consumer Products Inc (Symbol: REYN) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Reynolds Consumer Products Inc an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of REYN entered into oversold territory, changing hands as low as $20.695 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Reynolds Consumer Products Inc, the RSI reading has hit 29.8 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 42.3. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, REYN's recent annualized dividend of 0.92/share (currently paid in quarterly installments) works out to an annual yield of 4.39% based upon the recent $20.955 share price. A bullish investor could look at REYN's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on REYN is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out what 9 ...

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Kinsale Capital Group Inc (Symbol: KNSL) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Kinsale Capital Group Inc an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of KNSL entered into oversold territory, changing hands as low as $322.96 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Kinsale Capital Group Inc, the RSI reading has hit 25.6 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 42.3. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, KNSL's recent annualized dividend of 1/share (currently paid in quarterly installments) works out to an annual yield of 0.29% based upon the recent $348.30 share price. A bullish investor could look at KNSL's 25.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on KNSL is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out what 9 other oversold...

In trading on Thursday, shares of the Proshares S&P 500 EX-Health Care ETF (Symbol: SPXV) crossed below their 200 day moving average of $72.27, changing hands as low as $71.73 per share. Proshares S&P 500 EX-Health Care shares are currently trading down about 0.7% on the day. The chart below shows the one year performance of SPXV shares, versus its 200 day moving average: Looking at the chart above, SPXV's low point in its 52 week range is $51.95 per share, with $76.40 as the 52 week high point — that compares with a last trade of $71.92. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. First Financial Bankshares, Inc. (Symbol: FFIN) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making First Financial Bankshares, Inc. an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of FFIN entered into oversold territory, changing hands as low as $40.38 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of First Financial Bankshares, Inc., the RSI reading has hit 29.98 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 44.2. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, FFIN's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.45% based upon the recent $41.33 share price. A bullish investor could look at FFIN's 29.98 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on FFIN is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out...

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Centerspace (Symbol: CSR) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Centerspace an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of CSR entered into oversold territory, changing hands as low as $58.44 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Centerspace, the RSI reading has hit 29.8 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 42.3. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, CSR's recent annualized dividend of 3.08/share (currently paid in quarterly installments) works out to an annual yield of 5.17% based upon the recent $59.60 share price. A bullish investor could look at CSR's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on CSR is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out what 9 other oversold dividend stocks you need to know about » Also see...

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. PPG Industries Inc (Symbol: PPG) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making PPG Industries Inc an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of PPG entered into oversold territory, changing hands as low as $119.14 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of PPG Industries Inc, the RSI reading has hit 29.6 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 46.9. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, PPG's recent annualized dividend of 2.36/share (currently paid in quarterly installments) works out to an annual yield of 1.93% based upon the recent $122.03 share price. A bullish investor could look at PPG's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on PPG is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out what 9 other oversold dividend stocks you ne...

This article first appeared on GuruFocus. Alphabet (GOOGL, Financials) is stepping deeper into government AI work, taking advantage of a recent setback involving rival Anthropic and the U.S. Department of Defense. According to sources, Google swiftly strengthened its position when Anthropic and the Pentagon disagreed on military AI deployment. At that time, Google Cloud CEO Thomas Kurian pitched a wider range of AI technologies to senior Pentagon officials. The efforts seem to be paying off. The Pentagon considered Anthropic a supply chain risk and pursued other alliances, including OpenAI. Google also extended its Gemini for Government initiative, which lets military personnel design AI-powered solutions for non-classified activities. The firm reported over one million users of its AI systems across different U.S. military services. This magnitude shows Google is not simply experimenting, but becoming a major role in government AI infrastructure. The move also shows how competitive AI is, especially for huge, long-term national security contracts. Government adoption may give Google with a strategic cash source beyond advertising. Google's ability to turn these new partnerships into long-term defense contracts and scale its AI products in government organizations will be the next spark.

Three years after saying it had stopped buying location data of Americans without a warrant, the FBI acknowledged it has restarted the purchases. During questioning at a Senate Select Committee on Intelligence hearing yesterday, FBI Director Kash Patel said the location data purchases have produced valuable information, and he did not commit to stopping the practice. In March 2023, then-FBI Director Christopher Wray confirmed that the agency had previously bought location data of US citizens without obtaining a warrant. "To my knowledge, we do not currently purchase commercial database information that includes location data derived from Internet advertising,” Wray, who led the agency during Trump's first term and during the Biden era, said at the time. “I understand that we previously—as in the past—purchased some such information for a specific national security pilot project. But that’s not been active for some time.” At yesterday's hearing , Sen. Ron Wyden (D-Ore.) recounted Wray's 2023 statement and asked Patel, "Is that the case still and, if so, can you commit this morning to not buying Americans' location data?" Read full article Comments

In trading on Thursday, shares of the ProShares Large Cap Core Plus ETF (Symbol: CSM) crossed below their 200 day moving average of $75.87, changing hands as low as $75.69 per share. ProShares Large Cap Core Plus shares are currently trading down about 0.8% on the day. The chart below shows the one year performance of CSM shares, versus its 200 day moving average: Looking at the chart above, CSM's low point in its 52 week range is $55.06 per share, with $80.83 as the 52 week high point — that compares with a last trade of $75.69. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Thursday, shares of the ProShares Short 20+ Year Treasury ETF (Symbol: TBF) crossed below their 200 day moving average of $24.07, changing hands as low as $24.03 per share. ProShares Short 20+ Year Treasury shares are currently trading off about 0.7% on the day. The chart below shows the one year performance of TBF shares, versus its 200 day moving average: Looking at the chart above, TBF's low point in its 52 week range is $22.7201 per share, with $25.73 as the 52 week high point — that compares with a last trade of $24.06. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Thursday, shares of the iShares CMBS ETF (Symbol: CMBS) crossed below their 200 day moving average of $48.96, changing hands as low as $48.80 per share. iShares CMBS shares are currently trading off about 0.1% on the day. The chart below shows the one year performance of CMBS shares, versus its 200 day moving average: Looking at the chart above, CMBS's low point in its 52 week range is $47.45 per share, with $50.0899 as the 52 week high point — that compares with a last trade of $48.96. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In trading on Thursday, shares of the Teucrium Sugar Fund ETF (Symbol: CANE) crossed above their 200 day moving average of $10.13, changing hands as high as $10.33 per share. Teucrium Sugar Fund shares are currently trading up about 3.2% on the day. The chart below shows the one year performance of CANE shares, versus its 200 day moving average: Looking at the chart above, CANE's low point in its 52 week range is $8.97 per share, with $12.83 as the 52 week high point — that compares with a last trade of $10.30. Click here to find out which 9 other ETFs recently crossed above their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Central Asia Metals plc press release ( CAMLF ): FY Group revenue of $229.9 million. Net loss of $75.2 million (2024 restated net profit: $51.2 million), after an impairment charge of $117.8 million. 2026 outlook - Production guidance for 2026: o Copper of 12,000 to 13,000 tonnes o Zinc-in-concentrate of 18,000 to 20,000 tonnes o Lead-in-concentrate of 26,000 to 28,000 tonnes - Capex guidance for 2026 of between $14.5 million and $17.5 million, compared with $19.0 million spent in 2025. More on Central Asia Metals plc Central Asia Metals plc 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for Central Asia Metals plc Dividend scorecard for Central Asia Metals plc Financial information for Central Asia Metals plc

业内消息人士告诉媒体，由于谈判复杂，加拿大联邦政府和产油省阿尔伯塔预计无法在他们自行设定的4月1日截止日期前就碳定价达成协议。 加拿大总理卡尼去年撤销了特鲁多的一些气候政策，因为新政府在特朗普总统领导下与美国关系紧张之际，寻求优先考虑经济增 长和 能源出口。 加拿大联邦政府去年秋天誓言，将优先考虑有效的碳市场、加强甲烷法规以及碳捕集与封存等技术，作为减少石油和天然气排放的主要手段。 卡尼政府表示将废除特鲁多有争议的排放上限计划。 卡尼政府在2025年预算中的气候竞争力战略承认，需要减少石油和天然气行业的排放，以确保加拿大能够进入优先考虑可持续性的市场。 该计划称，卡尼的气候战略“基于推动投资而非禁令，基于结果而非目标”。 然而，由于谈判艰难，关于与阿尔伯塔省达成更强有力的工业碳定价政策协议的谈判可能会超过4月1日的最后期限。 据消息人士称，一些大型油砂生产商正在抵制联邦政府计划中的某些要点。 加拿大能源和自然资源部长蒂姆·霍奇森已承认，协议可能会面临小幅延迟。 据报道，霍奇森曾表示：“众所周知，达成交易有时会正好在截止日期前完成，有时会稍微超出截止日期。” 这种不确定性正在推迟油砂碳捕集项目的投资。 最大的生产商之一 加拿大自然资源 公司本月早些时候表示，将推迟其在Albian油砂矿扩建中价值60亿美元的Jackpine碳捕集项目，“原因是政府关于碳定价和甲烷的监管政策尚未最终确定，这给长期增长投资带来了不确定性和经济负担。” 加拿大自然资源公司表示：“一旦这些监管政策、审批时间表和出口通道更加确定，我们将重新评估该项目的可行性。” 责任编辑：张俊 SF065

欧洲央行管理委员会成员Yannis Stournaras警告称，若中东战争持续，可能会造成重大经济后果。 “这一地缘政治冲突对全球及欧元区经济构成额外的负面供给冲击，若冲突持续或蔓延至更多国家，可能会产生巨大的宏观经济影响，”这位希腊央行行长在法兰克福一场活动上表示。 就在几小时前，欧洲央行宣布维持利率不变，同时警告称能源成本上升将带来通胀上行风险。知情人士此前表示，如果伊朗战争的波及效应导致通胀远超目标，官员们不排除在4月加息的可能性。 “冲突时期往往带来预算紧张、能源中断以及更广泛的不确定性 —— 这使得稳健的财政治理和协调一致的危机管理尤为重要，”Stournaras表示。 他还呼吁欧洲各国政府扩大共同举债，以实现特定目标。 责任编辑：丁文武